Tasigna 150mg and 200mg are indicated for the treatment of adult patients with newly diagnosed
Philadelphia chromosome positive chronic myeloid leukaemia (CML) in the chronic phase.
Tasigna 200mg only is indicated also for the treatment of Philadelphia chromosome positive chronic
myeloid leukaemia (Ph+CML) in chronic phase or accelerated phase in patients resistant to or
experiencing significant toxicity during treatment with imatinib.